Evidence map›Paper›PMID 32977707›Full record

ReviewMolecules (Basel, Switzerland)2020

Utilization of Polymer-Lipid Hybrid Nanoparticles for Targeted Anti-Cancer Therapy.

Ayeskanta Mohanty, Saji Uthaman, In-Kyu Park

Abstract readReview
PubMed Full text at PMC Publisher
In one paragraph

Review in Molecules (Basel, Switzerland), 2020. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 70 papers.

0numbers the graph read from it
0cells of the map it votes in
70citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

70 citing papers in PubMed.

  1. Review
  2. Review
  3. Article
  4. Review
  5. Advancing brain immunotherapy through functional nanomaterials.Drug delivery and translational research · 2026
    Review
  6. Review
  7. Review
  8. Article
  9. Review
  10. Review
  11. Review
  12. Review
  13. Review
  14. Article
  15. Review
  16. Review
  17. Review
  18. Review
  19. Review
  20. Article

10 more citing papers are in PubMed but not listed here.

4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

3 authors.

Ayeskanta MohantyDepartment of Biomedical Sciences, Chonnam National University Medical School, 264, Seoyang-ro, Jeollanam-do 58128, Korea.
Saji UthamanDepartment of Polymer Science and Engineering, Chungnam National University, 99 Daehak-ro, Yuseoung-gu, Daejeon 34134, Korea.ORCID 0000-0001-6387-7510
In-Kyu ParkDepartment of Biomedical Sciences, Chonnam National University Medical School, 264, Seoyang-ro, Jeollanam-do 58128, Korea.ORCID 0000-0003-1616-9153

Funding

National Research Foundation of Korea 2017M3A9E2056372National Research Foundation of Korea 2020R1A2C2005620, 2018R1A5A2024181 and 2019M3E5D1A02068082
6 · The paper itself

Abstract

Cancer represents one of the most dangerous diseases, with 1.8 million deaths worldwide. Despite remarkable advances in conventional therapies, these treatments are not effective to completely eradicate cancer. Nanotechnology offers potential cancer treatment based on formulations of several nanoparticles (NPs). Liposomes and polymeric nanoparticle are the most investigated and effective drug delivery systems (DDS) for cancer treatment. Liposomes represent potential DDS due to their distinct properties, including high-drug entrapment efficacy, biocompatibility, low cost, and scalability. However, their use is restricted by susceptibility to lipid peroxidation, instability, burst release of drugs, and the limited surface modification. Similarly, polymeric nanoparticles show several chemical modifications with polymers, good stability, and controlled release, but their drawbacks for biological applications include limited drug loading, polymer toxicity, and difficulties in scaling up. Therefore, polymeric nanoparticles and liposomes are combined to form polymer-lipid hybrid nanoparticles (PLHNPs), with the positive attributes of both components such as high biocompatibility and stability, improved drug payload, controlled drug release, longer circulation time, and superior in vivo efficacy. In this review, we have focused on the prominent strategies used to develop tumor targeting PLHNPs and discuss their advantages and unique properties contributing to an ideal DDS.

Indexed as

AnimalsHumansLipidsMolecular Targeted TherapyNanoparticlesNeoplasmsPolymersLipidsPolymersanticancer therapycancerliposomesnanotechnologypolymeric nanoparticlespolymer-lipid hybrid nanoparticles (PLHNPs)targeting ligands

Identifiers

PMID32977707
PMCPMC7582728

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.